The Life Sciences team advised Century Therapeutics, Inc. in its launch with $250 million in financing from Bayer, Versant Ventures and Fujifilm Cellular Dynamics Inc. (FCDI). The proceeds will enable Century to advance to multiple programs into the clinic for hematologic and solid malignancies.
Philadelphia-based Century Therapeutics is harnessing the power of adult stem cells to develop curative allogeneic cell therapies for cancer. Century’s genetically-engineered, induced pluripotent stem cell- (iPSC) derived immune effector cell products are designed to specifically target hematologic and solid cancers. Century was founded by healthcare investment firm Versant in 2018 and later that year formed a strategic partnership with FCDI, a developer and manufacturer of human iPSCs. The announcement establishes Leaps by Bayer, the venture investment arm of the global life sciences company Bayer, as an integral partner in Century’s investor syndicate.
The Goodwin team was led by partner Mitchell Bloom, and included partners Rob Puopolo, Dan Karelitz, Noelle Dubiansky, Beth Withers and Rich Matheny, and associates Ryan LaForce, Robert Dzialo, Shannyn Henke, Joshua Eisenson, Trevor Skelly and Justin Pierce.
For more details, read the articles in The Wall Street Journal, FierceBiotech and BioPharma Dive.